Knight Therapeutics Inc. (OTCMKTS:KHTRF) Short Interest Up 7.2% in January

Knight Therapeutics Inc. (OTCMKTS:KHTRF) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 376,600 shares, a growth of 7.2% from the December 31st total of 351,200 shares. Based on an average trading volume of 1,900 shares, the short-interest ratio is presently 198.2 days.

Knight Therapeutics Stock Performance

Shares of Knight Therapeutics stock traded down $0.19 on Monday, hitting $3.77. 1,602 shares of the company’s stock traded hands, compared to its average volume of 1,533. Knight Therapeutics has a one year low of $3.48 and a one year high of $4.55. The firm’s 50-day moving average price is $3.75 and its two-hundred day moving average price is $3.99.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.